Our Science


A novel antifungal

Ibrexafungerp is the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids.

It has broad spectrum activity encompassing Candida, Aspergillus, Pneumocystis, Dimorphic fungi and mucorales, including multi-drug resistant (MDR) species and pan resistant species such as Candida auris. Ibrexafungerp combines the well-established activity of glucan synthase inhibitors with the flexibility of oral and IV formulations, offering a broad use across different settings (in-patient and out-patient).

Ibrexafungerp has the potential to be an essential therapy in the treatment of multiple serious fungal infections:

  • Novel glucan synthase inhibitor
  • Potent activity against most common fungi pathogens, including those resistant to other antifungals


  • Broad spectrum (including multidrug-resistant strains)

    Fungicidal vs. Candida

  • Convenient oral dosing

  • High tissue penetration

    High concentrations in tissues of interest, except CNS

  • Favorable safety profile and well tolerated

    ~2,000 subjects exposed
    Low risk of drug-drug interactions

  • Worldwide rights and long exclusivity (patent protection up to 2035)

    Qualified Infectious Disease Product (QIDP), Fast Track and Orphan Drug status for invasive candidiasis and aspergillosis

Ibrexafungerp is an investigational drug. Items listed above illustrate ibrexafungerp target attributes.

Interested in our clinical trials?

Find out more about what trials are going on presently.

Learn More

Our Data

SCYNEXIS regularly presents key infectious disease study data at top medical meetings.

Learn More